Clinicians expectations about CFTR modulator therapy
The vast majority of clinicians declared to expect moderate to great
improvements in lung disease (88%), nutritional status (90%), ability
to perform activities of daily living (86%) and survival (76%) but
none or slight effect on exocrine pancreatic sufficiency (71%),
endocrine pancreatic function (71%) and liver disease (78%). More
specifically, clinicians expect moderate to great improvement on the
number of exacerbations (95%) and slowing down of annual decline in
FEV1 (86%) but none or slight increase in FEV1 (63%) and little or no
improvement of pulmonary imaging (59%).